After co‐treatment, the IDO inhibitor could successfully lower the IDO activity induced by the TLR 7/8a at the cellular level (DCs and 4T1 tumor cells) (Figure 5) and at the tissue levels (tumor and TDLN) (Figure 6). The gene discussed is IDO1; the disease is neoplasm.